GlassScriptPhysician profile
David A Hall
NPI 1710418470
$1,711.86
in general payments reported to CMS, 2019-2025
19 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.93 · 2020: $35.67 · 2021: $478 · 2022: $187 · 2023: $466 · 2024: $278 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.83 | 2021-2025 | |
| Pfizer INC. | $220.80 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $175.94 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $149.12 | 2020-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $146.74 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $137.35 | 2022-2023 | |
| Glaxosmithkline, LLC. | $112.65 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $92.45 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $86.02 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $36.82 | 2021-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $29.50 | 2021 | |
| Amgen INC. | $29.04 | 2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $21.77 | 2021 | |
| Astellas Pharma US INC | $17.92 | 2020 | |
| Csl Behring | $16.94 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.12 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $13.78 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $7.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.